retatrutide clinical trial results obesity just delivered the first top-line Phase 3 for a triple agonist in โ and the findings from TRIUMPH-4 are striking๐ VisualAbstract: Retatrutide reduces body weight
Description
Because anti-obesity medication is usually optional rather than standard, your benefits depend on what your employer chooses to include in your plan
Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors simultaneously, whereas semaglutide targets only GLP-1 and tirzepatide targets GLP-1 and GIP
Adverse event-related discontinuation rates were 8% among liraglutide-treated patients compared to 4% of placebo recipients [44]
Can GLP-1 Drugs Be Repurposed for Depression
Studies suggest that certain types of foods can stimulate the release of GLP-1 and other appetite-regulating hormones
